AbbVie expects to return to “robust” growth in fiscal 2025. On the aesthetics side of the business, demand for cosmetic products like Botox and facial fillers hasn’t fully returned from a ...

For 20 years, AbbVie’s Humira (adalimumab) was one of the world’s top-selling products, but its patent expiry, and the subsequent entry of biosimilars in January 2023 resulted in a 32% decline ...